MDxHealth SA (NASDAQ:MDXH) Short Interest Update

MDxHealth SA (NASDAQ:MDXH - Get Free Report) saw a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 41,100 shares, a decrease of 42.8% from the May 15th total of 71,900 shares. Approximately 0.1% of the company's stock are sold short. Based on an average daily volume of 67,700 shares, the days-to-cover ratio is currently 0.6 days.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of MDxHealth to a "hold" rating in a report on Saturday, May 24th.

MDxHealth Stock Performance

Shares of MDXH remained flat at $1.97 during trading hours on Wednesday. The stock had a trading volume of 58,906 shares, compared to its average volume of 88,349. The company has a debt-to-equity ratio of 13.81, a quick ratio of 1.92 and a current ratio of 2.00. The company has a market capitalization of $93.16 million, a P/E ratio of -1.72 and a beta of 1.30. The company's 50 day simple moving average is $1.88 and its 200 day simple moving average is $1.88. MDxHealth has a 52 week low of $1.35 and a 52 week high of $3.50.

MDxHealth (NASDAQ:MDXH - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The company had revenue of $24.29 million during the quarter, compared to analyst estimates of $22.62 million. MDxHealth had a negative return on equity of 492.11% and a negative net margin of 41.02%. As a group, equities analysts forecast that MDxHealth will post -1.15 earnings per share for the current fiscal year.

Institutional Trading of MDxHealth

Institutional investors and hedge funds have recently modified their holdings of the company. Oppenheimer & Co. Inc. grew its stake in MDxHealth by 100.0% in the 4th quarter. Oppenheimer & Co. Inc. now owns 20,000 shares of the company's stock valued at $47,000 after buying an additional 10,000 shares during the last quarter. Perkins Capital Management Inc. boosted its holdings in MDxHealth by 31.6% during the fourth quarter. Perkins Capital Management Inc. now owns 983,475 shares of the company's stock valued at $2,331,000 after acquiring an additional 236,100 shares during the period. Geode Capital Management LLC acquired a new stake in shares of MDxHealth in the fourth quarter valued at about $25,000. Samjo Management LLC grew its position in shares of MDxHealth by 130.9% in the fourth quarter. Samjo Management LLC now owns 1,824,312 shares of the company's stock valued at $4,324,000 after purchasing an additional 1,034,312 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of MDxHealth by 715.2% in the fourth quarter. Renaissance Technologies LLC now owns 123,100 shares of the company's stock worth $292,000 after purchasing an additional 108,000 shares during the period.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.